Shares last traded at $2.25 which is marginally higher than the 50 day moving average of $2.06 and quite a bit higher than the 200 day moving average of $1.83. The 50 day moving average went up by +9.17% and the 200 day average moved up $0.42. Histogenics Corporation shares had a trading volume of 1,318 on Tuesday. Shares saw a steep decrease in trading volume of 96.11% under the normal average daily volume.
Traders are more bullish on shares of Histogenics Corporation recently looking at the motion in short interest. The company had a fall in short interest of -9.19% as of September 29, 2017 from the last reporting period. Short shares decreased 2,346 over that period. Days to cover decreased 0.0 to 0.0 and the percentage of shorted shares was 0.00% on September 29.
These firms have modified their investment in HSGX. As of the end of the quarter Blackrock Inc. had sold a total of 1,659 shares trimming its position 55.1%. The value in dollars decreased from $5,000 to $2,000 decreasing 60.0% quarter over quarter. Carl Domino Inc downsized its ownership by selling 7,900 shares a decrease of 8.8% from 03/31/2017 to 06/30/2017. Carl Domino Inc currently owns 81,500 shares with a value of $146,000. The total value of its holdings decreased 5.8%.
Sabby Management, LLC cut its investment by shedding 11,027 shares a decrease of 1.0%. Sabby Management, LLC claims 1,084,395 shares valued at $1,952,000. The value of the position overall is up by 3.0%. As of quarter end Ubs Group Ag had disposed of 2,876 shares trimming its stake by 26.6%. The value of the total investment in Histogenics Corporation went from $19,000 to $14,000 a change of 26.3% since the last quarter.
In the latest earnings report the EPS was $-1.43 and is expected to be $-1.09 for the current year with 22,490,000 shares currently outstanding. Next quarter’s EPS is expected be $-0.24 with next year’s EPS anticipated to be $-0.81.
Histogenics Corporation, launched on July 14, 2006, is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Business’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. The Company uses regenerative medicine platform to develop its products. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Business’s Tissue Engineering Processor (TEP). The Business’s TEP is designed to mimic the conditions found in a joint so that the implant is prepared to begin functioning like normal healthy cartilage prior to implantation. When NeoCart is implanted, a bioadhesive is used to anchor NeoCart in the cartilage injury and seal the implant to the surrounding native cartilage interface..